Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Revenue (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Revenue for 16 consecutive years, with $247.1 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 29.64% to $247.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $883.4 million through Dec 2025, up 43.78% year-over-year, with the annual reading at $883.4 million for FY2025, 43.78% up from the prior year.
  • Revenue hit $247.1 million in Q4 2025 for Ani Pharmaceuticals, up from $227.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $247.1 million in Q4 2025 to a low of $11.2 million in Q1 2021.
  • Historically, Revenue has averaged $123.7 million across 5 years, with a median of $124.1 million in 2023.
  • Biggest five-year swings in Revenue: tumbled 77.5% in 2021 and later surged 475.69% in 2022.
  • Year by year, Revenue stood at $60.9 million in 2021, then skyrocketed by 54.66% to $94.2 million in 2022, then skyrocketed by 39.71% to $131.7 million in 2023, then surged by 44.75% to $190.6 million in 2024, then increased by 29.64% to $247.1 million in 2025.
  • Business Quant data shows Revenue for ANIP at $247.1 million in Q4 2025, $227.8 million in Q3 2025, and $211.4 million in Q2 2025.